
#cgajc Jewel, I wanted to congratulate you on your important work and clinical trials. We finally have a medical option for FAP patients with advanced duodenal disease. Still questions to be answered but already a game-changer.
Jewel Samadder
21 posts


#cgajc Jewel, I wanted to congratulate you on your important work and clinical trials. We finally have a medical option for FAP patients with advanced duodenal disease. Still questions to be answered but already a game-changer.

#CGAjc If we have patients who might qualify, how best to get them into the trial? Can you provide inclusion criteria for current study?

#CGAjc If we have patients who might qualify, how best to get them into the trial? Can you provide inclusion criteria for current study?

#CGAjc Do you think erlotinib would be effective on its own or is it a combined effect with COX inhibition? Is there any way to predict who will be more likely to respond?

#cgajc When do you anticipate completing the current erlotinib trial? Will be interesting to see if same efficacy but less rash. Would be ideal.



#cgajc Any concerns about pulmonary toxicity with erlotinib longer term? Someone mentioned this as a concern for polyposis indication. Don't remember this being a problem in your trial. @CGAIGC


#CGAjc Coming to the jc a bit late but I wanted to ask Jewel about insurance coverage. I've had trouble getting coverage for erlotinib. Any advice? @CGAIGC

If a drug were to shrink polyps and downstage the patient, benefit is to avoid a Whipple or need for aggressive endoscopy procedures such as EMR. These have significant morbidity. #CGAjc twitter.com/RachelP_LGC/st…

@J_Samadder what is the selling point for patients? Less surgery? Less endoscopy? #CGAjc


.@J_Samadder many who do not specialize *specifically* in polyposis may be unfamiliar w/ new therapies (incl. those in trials). What are potential benefits/risks vs current, better known treatments? #CGAjc #GCchat

There are alot of exciting trials in FAP starting or ongoing. 1) NCI trial of low dose erltoinib running at 7 centers. 2) DFMO-Sulindac trial wrapping up, results will be ready for DDW in 2019. 3) Upcoming pharma trials also in works. #CGAjc twitter.com/gcleslieb/stat…

CGA twitter journal club is happening NOW! Follow along & submit ?s using #CGAjc // #GCchat #crcsm twitter.com/cgaigc/status/…

Was it a diffuse rash? Any predilection for an area (ie face)? Just thinking that for my young patients especially might be an issue. #CGAjc twitter.com/J_Samadder/sta…

